Effect of PCSK9 Inhibitor on Blood Lipid Levels in Patients with High and Very-High CVD Risk: A Systematic Review and Meta-Analysis

OBJECTIVES: We aimed to investigate the effects of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor on blood lipid levels in patients with high and very-high cardiovascular risk. DESIGN: 14 trials (n = 52,586 patients) comparing treatment with or without PCSK9 inhibitors were retrieve...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yue, Suo, Yanrong, Yang, Lin, Zhang, Xiaolu, Yu, Qun, Zeng, Miao, Zhang, Wenlan, Jiang, Xijuan, Wang, Yijing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9072011/
https://www.ncbi.nlm.nih.gov/pubmed/35529059
http://dx.doi.org/10.1155/2022/8729003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9072011/
https://www.ncbi.nlm.nih.gov/pubmed/35529059
http://dx.doi.org/10.1155/2022/8729003

Ejemplares similares